---
title: "MaxCyte (MXCT) Gets a Buy from Stifel Nicolaus"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286285778.md"
description: "MaxCyte (MXCT) has received a Buy rating from Stifel Nicolaus, with a price target of $4.00, as reported by Daniel Arias. Arias, who focuses on the Healthcare sector, has an average return of -0.2% and a 41.35% success rate on his stock recommendations. Additionally, Craig-Hallum's Matt Hewitt also issued a Buy rating for MaxCyte today, while BTIG maintained a Hold rating on the stock."
datetime: "2026-05-13T15:16:40.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286285778.md)
  - [en](https://longbridge.com/en/news/286285778.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286285778.md)
---

# MaxCyte (MXCT) Gets a Buy from Stifel Nicolaus

In a report released today, Daniel Arias from Stifel Nicolaus maintained a Buy rating on MaxCyte, with a price target of $4.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Arias covers the Healthcare sector, focusing on stocks such as Revvity, Qiagen, and Repligen. According to TipRanks, Arias has an average return of \-0.2% and a 41.35% success rate on recommended stocks.

In addition to Stifel Nicolaus, MaxCyte also received a Buy from Craig-Hallum’s Matt Hewitt in a report issued today. However, on the same day, BTIG reiterated a Hold rating on MaxCyte (NASDAQ: MXCT).

### Related Stocks

- [MXCT.US](https://longbridge.com/en/quote/MXCT.US.md)
- [SF.US](https://longbridge.com/en/quote/SF.US.md)
- [RVTY.US](https://longbridge.com/en/quote/RVTY.US.md)
- [QGEN.US](https://longbridge.com/en/quote/QGEN.US.md)
- [QIA.DE](https://longbridge.com/en/quote/QIA.DE.md)
- [RGEN.US](https://longbridge.com/en/quote/RGEN.US.md)
- [SF-C.US](https://longbridge.com/en/quote/SF-C.US.md)
- [SFB.US](https://longbridge.com/en/quote/SFB.US.md)
- [SF-B.US](https://longbridge.com/en/quote/SF-B.US.md)
- [SF-D.US](https://longbridge.com/en/quote/SF-D.US.md)

## Related News & Research

- [River Global Investors Discloses Investment in MaxCyte with 6.1% Stake](https://longbridge.com/en/news/286427947.md)
- [Craig-Hallum Remains a Buy on MaxCyte (MXCT)](https://longbridge.com/en/news/286155462.md)
- [LifeSci Capital Sticks to Their Buy Rating for MoonLake Immunotherapeutics (MLTX)](https://longbridge.com/en/news/286649191.md)
- [Damora Therapeutics (DMRA) Receives a Rating Update from a Top Analyst](https://longbridge.com/en/news/286678740.md)
- [LifeSci Capital Sticks to Its Buy Rating for Neurogene (NGNE)](https://longbridge.com/en/news/286648209.md)